Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Future Star: Organ-preserving strategy in stage II–III NSCLC after neoadjuvant therapy
ChiCTR2500115167Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Dec 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of almonertinib, ensartinib and adebrelimab in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Event-free survival. Started Dec 2025; status: recruiting.
02
Drugs
almonertinibensartinibadebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500115167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115167.